GoldenGolden
Xealth

Xealth

A platform for digital health in Washington that focuses on enabling clinicians to easily integrate, prescribe and monitor digital health tools for patients from their EHR workflows. 

Xealth is a platform for digital health in Washington that focuses on enabling clinicians to easily integrate, prescribe and monitor digital health tools for patients from their EHR workflows. Founded 2015 in Seattle, Washington, United States by Aaron Sheedy, Eric Fu, Mike McSherry and Sundar Balasubramanian, Xealth has raised a total of $22.5M in funding over three rounds. Their latest funding was raised on June 20, 2019 from a Series A round. As of March 2020, Xealth is funded by 12 investors. Atrium Health and Cleveland Clinic are the most recent investors as of March 2020. Xealth spun out of Providence St. Joseph Health (PSJH) in 2017, and its other investors include McKesson Ventures, Novartis, Philips, and ResMed as well as Providence Ventures, UPMC and the Froedtert and Medical College of Wisconsin Health Network.

Timeline

June 20, 2019
Xealth raises a $3,000,000 series A round from Atrium health.
April 2019
Xealth raises a $11,000,000 series A round from Froedtert & the Medical College of Wisconsin, Novartis, Philips, Providence Ventures, ResMed and Threshold Ventures.
March 2019
Xealth raises a $11,000,000 series A round from Froedtert & the Medical College of Wisconsin, McKesson Ventures, Novartis, Philips, Providence Ventures, ResMed, Threshold Ventures and UPMC.
2015
Founded

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Xealth funding round, March 2019
11,000,000
March 2019
5 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

David Cooper, Psy.D.

Employee

Ed Pedini

Employee

Eric Fu

Employee

Mike Mcsherry

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.